Objective: Contrast agent is a potential risk factor for acute kidney injury (AKI). Little is known about the incidence of contrast-induced nephropathy (CIN) after trans-apical aortic valve implantation (TA-AVI) and on the impact of contrast exposure during preoperative computed tomography (CT) scan and cardiac catheterization. Methods: A total of 270 consecutive high-risk patients received TA-AVI for symptomatic aortic valve stenosis during a 3-year period. Different preoperative, peri-procedural, and postoperative variables were analyzed by uni-and multivariate logistic regression concerning incidence of early (<7 days) AKI and need for renal replacement therapy (RRT). Nine patients on chronic preoperative dialysis were excluded. Results: Mean age was 82 AE 5.8 years, 71% were female. LogEuroSCORE (European System for Cardiac Operative Risk Evaluation) and STS Score were 31.4 AE 15.6% and 12.1 AE 7.4%, respectively. Preoperative estimated glomerular filtration rate (eGFR) <60 ml min À1 was present in 35.2%. CT scan and cardiac catheterization within 7 days before TA-AVI were performed in 43.7% and 20.3% of the patients and were associated with a mean contrast-agent exposition of 110 AE 21 ml for CT scans and 91 AE 65 ml for cardiac catheterization. Regarding the postoperative renal outcome, an improved or at least stable eGFR was seen in more than 50% of the patients. Intraoperative contrast-agent application was 99 AE 64 ml and correlated significantly to the development of postoperative AKI and need for RRT ( p = 0.013 and p = 0.003). Postoperative RRT was required in 15.7%. Chronic renal insufficiency (odds ratio (OR) = 6.8, p = 0.025) and number of blood transfusions (OR = 8.8, p = 0.009) were independent risk factors for RRT. Postoperative AKI occurred in 16.1% and intra-operative contrastagent burden >99 ml (OR = 2.3, p = 0.038), new thrombocytopenia (OR = 4.4, p = 0.005) and pathological leucocyte count (OR = 2.8, p = 0.009) were independent risk factors for this event. Early (within 1-7 days before TA-AVI) preoperative CT and cardiac catheterization did not significantly increase incidence of RRT or AKI. Short-term and long-term survival was explicitly lower in the AKI and in the RRT groups ( p < 0.001 each). Conclusions: GFR improves after TA-AVI. Postoperative AKI and RRT depend on the amount of intra-operative contrast agent. These results strongly support the need for intra-operative tools to reduce contrast-agent exposition during TA-AVI. #
Introduction
Contrast agent is a known risk factor for acute kidney injury (AKI), which is associated with higher mortality after cardiac surgery [1, 2] . The incidence of AKI after conventional cardiac surgery varies between 1% and 30% [3] . Transcatheter aortic valve implantation (T-AVI) evolved as a truly minimally invasive strategy to treat elderly high-risk patients with severe aortic stenosis [4] . One of the advantages of T-AVI is the avoidance of cardiopulmonary bypass (CPB) as one of the most important risk factors for AKI after cardiac surgery. In contradiction, the use of a contrast agent during T-AVI is a new risk factor for AKI. Little is known about the incidence of contrast-induced nephropathy (CIN) after T-AVI. The currently published literature indicates AKI between 11.7% and 57% [5] [6] [7] .
Patient screening for T-AVI includes cardiac catheterization routinely and computed tomography (CT) in some of the patients. Performing those examinations during the same hospital stay and thus close to the T-AVI procedure may be practical, but may also lead to an increased risk of AKI due to higher contrast load [8] . Therefore, the aim of this study was to determine the incidence and risk factors for early AKI, including renal replacement therapy (RRT) after T-AVI, with a special focus on the impact on preoperative contrast-agent application for cardiac catheterization and CT scan.
Methods

Patient selection, study design
Between February 2006 and October 2009, 270 consecutive high-risk patients with symptomatic severe aortic stenosis received trans-apical AVI (TA-AVI) at our institution. Nine patients with preoperative chronic dialysis were excluded.
All patients were discussed in an interdisciplinary team conference; after informed consent, all patients underwent TA-AVI using the Edwards SAPIEN valve (Edwards Lifescience, Irvine, CA, USA). The local Institutional Review Board granted approval.
The time between preoperatively performed cardiac catheterization and/or CT scan and the associated amount of contrast agent was recorded.
All data were routinely collected prospectively using medical records and a computerized database, and were analyzed retrospectively. Primary end point was renal outcome including development of AKI and necessity of RRT. Secondary end points included length of stay (LOS), 30-day and in-hospital mortality as well as follow-up survival until February 2010.
Trans-apical aortic valve implantation
In all patients, a left anterolateral mini-thoracotomy was performed through the fifth or sixth intercostal space, the left ventricular apex was exposed and secured by two 2/0 Prolene purse-strings. After apical puncture, a soft guidewire was advanced over the stenotic valve followed by a soft-tip 14F sheath. By using a right Judkins catheter, a super-stiff guidewire was anchored into the descending aorta. During rapid pacing, a 20F balloon valvuloplasty was performed, and the valve was positioned and implanted using a stepwise approach under a second short episode of rapid ventricular pacing with additional contrast visualization.
All implantations were performed in a fully equipped hybrid room with a high-quality imaging system by an interdisciplinary team involving cardiac surgeons, cardiologists, and anesthetists. Prior to skin incision, a femoral safety net was placed and a cardiopulmonary bypass system (CPB) was always available ready to use on standby.
Hemodynamics of the implanted valve was assessed by transesophageal echocardiography (TEE) and post-implant angiography.
After the procedure, all patients were transferred to the post-anesthetic recovery room for early extubation following an ultra-fast-track protocol, and were only transferred to the intensive care unit (ICU) when any instability occurred.
The amount of intra-operative contrast agent was recorded. Preoperative intravenous hydration was not routinely performed due to restricted heart function in most of the patients.
Creatinine measurement, acute kidney injury, and contrast agent
Creatinine levels prior to cardiac catheterization, CTscan, and TA-AVI were collected as well as the maximum level within 7 days after cardiac catheterization and CTscan. After TA-AVI, creatinine levels were recorded at several time points during the first 7 postoperative days in all patients. Estimated glomerular filtration rate (eGFR) was calculated with the simplified modification of diet in renal disease (MDRD) formula. Estimated GFR <60 ml min À1 /1.73 m 2 body surface was defined as chronic kidney disease.
Postoperative acute kidney injury (AKI) was defined according to the Risk, Injury, and Failure; and Loss, and End-stage kidney disease (RIFLE) criteria based on either eGFR or urine output [9] . RIFLE categorizes five classes of AKI: 1 = Risk (eGFR decrease >25% or increased serum creatinine 1.5-fold), 2 = Injury (eGFR decrease >50% or increased serum creatinine twofold), 3 = Failure (eGFR decrease >75% or increased serum creatinine threefold), 4 = Loss (complete loss of kidney function >4 weeks) and 5 = End stage kidney disease (>3 months). Due to incomplete urine output measurement, only eGFR was used as AKI criteria. AKI was also defined as sudden (within first 7 days) after surgery.
The indication to start temporary hemofiltration was based on clinical experience, serum potassium, urea levels, and urine output, and not only on the RIFLE criteria. The strategy was to start temporary hemofiltration early to allow for early and gentle dehydration. Thus, in some patients, early temporary renal replacement therapy was started based on clinical judgment without specifically matching the RIFLE criteria for AKI at that time.
Ultravist W (Bayer HealthCare, Switzerland) was routinely used as a non-ionic monomer and low-osmolar contrast agent.
Leucocyte and thrombocyte count as well as hemoglobin levels, including the number of blood transfusion units during the first 7 postoperative days, were recorded. Due to frequently observed transient changes in thrombocyte and leucocyte counts after cardiac surgery, only alterations that persisted for more than 2 days were considered as relevant.
Statistical analysis
Statistical analysis was performed using SPSS TM statistical package 18 (SPSS Inc., an IBM Company, Chicago, IL, USA). Quantitative variables were expressed as mean (standard deviation) or median (interquartile range), and qualitative variables as percentages. Continuous variables were compared using the Student's unpaired t-test or the analysis of variance (ANOVA) test. Categorical variables were compared by exact chi-square test. Univariate and multivariate logistic regression model with stepwise backward procedure was performed including eight preoperative and six peri-procedural binary variables, which may be relevant factors to initiate RRT, and using one preoperative and seven periprocedural binary variables for AKI. Univariate and multivariate analysis of risk factors was performed to calculate odds ratio (OR) with 95% confidence intervals (CIs). Kaplan-Meier survival analysis was performed for all patients. Differences were considered statistically significant at p-values < 0.05. ). Thirty-day and in-hospital mortality rates were 8.8% (n = 23) and 10.0% (n = 26), respectively. Complete periprocedural and postoperative outcomes are shown in Table 2 .
Results
Mean
Renal replacement therapy
Patients who needed RRT during the first 7 postoperative days were more frequently male (43.9 vs 27.7%, p = 0.043), had a higher STS-Score (15.0 vs 11.5%, p = 0.005), presented more frequently with peripheral vascular disease (34.1 vs 18.6%, p = 0.036), had lower preoperative hemoglobin (7.1 vs 7.5 mmol l À1 , p = 0.009) and lower eGFR (59.1 vs 78.6 ml min À1 1.73 m À2 , p < 0.001). Concomitant mitral regurgitation > grade I+ was also found to be more frequently present in the RRT group (52.9 vs 27.6%, p = 0.005). There was no significant difference between the two groups regarding timing and contrast-agent burden during preoperative cardiac catheterization and CT scans.
Patients with RRT had longer median procedure time (85 vs 71 min, p = 0.001) and higher median amount of contrast agent (115 vs 88 ml, p < 0.001). They showed a prolonged median ICU stay (46 vs 0 h, p = 0.001), and prolonged median ventilation time (7.5 vs 3.5 h, p < 0.001) with an explicitly higher 30-day and in-hospital mortality rate (34.1% vs 4.1% and 41.5% vs 4.1% respectively, both p < 0.001). Need for RRT was a risk factor for in-hospital mortality with an OR of 16.6. One-year survival was 33.3% in the RRT group versus 80.8% ( p < 0.001) in the non-RRT group (Fig. 1 ). All statistically significant differences of baseline characteristics, periprocedural characteristics, and postoperative outcomes are given in Table 3 . Independent predictors for RRT were preoperative serum creatinine levels >1.1 mg dl À1 (OR = 6.7), preoperative eGFR < 60 ml h À1 (OR = 6.8), number of transfused blood units > 5 (OR = 8.8), and postoperative leucocyte count > 12 G/l for more than 2 days (OR = 3.7; Table 4 ).
Acute kidney injury
Regarding the preoperative characteristics, the only significant difference between patients with AKI and without AKI was a higher STS-score in the AKI group (14.2 vs 11.7%, p = 0.040).
There was no significant difference between the two groups regarding timing and contrast-agent burden of preoperatively cardiac catheterization and CT scans.
Patients with AKI had longer median procedure time (80 vs 75 min, p = 0.011), showed prolonged median ICU stay (11.6 b After CC/CT-scan = minimum eGFR within 7 days after CC or CT-scan. c Total amount of contrast-agent = CC + CT-scan.
vs 0 h, p = 0.002), and prolonged median ventilation time (4.5 vs 3.5 h, p = 0.002). Use of CPB was more frequent in the AKI group (19 vs 7.8%, p = 0.040) as was conversion to sternotomy (7.1 vs 0.5%, p = 0.014). A larger number of patients with AKI had an intra-operative contrast-agent burden greater than median of 90 ml (66.7 vs 43.4%, p = 0.007). In-hospital and 30-day mortality rates were also higher in the AKI group (28.6 vs 6.4% and 26.2 vs 5.5%, respectively, both p < 0.001). AKI was a risk factor for inhospital mortality with an OR of 5.9. One-year survival was 45.2 in the AKI group versus 79.5% ( p < 0.001) in the non-AKI group (Fig. 2) . All statistically significant differences of baseline characteristics, peri-procedural characteristics, and postoperative outcomes are given in Table 5 . Independent predictors for AKI were intra-operative contrast-agent burden > median of 90 ml and 1.37 ml per kg body weight (OR = 2.3 and 2.5), new thrombocytopenia for more than 2 days (OR = 4.4), and leucocyte count > 12 G/l for more than 2 days (OR = 2.8; Table 6 ).
Discussion
T-AVI evolved as a truly minimally invasive technique to treat elderly high-risk patients with severe aortic stenosis. All values are expressed as [n/%] or mean AE SD, LOS: length of stay, eGFR: estimated glomerular filtration rate, AKI: acute kidney injury, RRT: renal replacement therapy. a Three patients due to coronary problems ! CABG procedure (two died in hospital), one patient due to aortic dissection Stanford A ! replacement of the ascending aorta and hemiarch (patient still alive).
b After the procedure all patients were transferred to the post-anesthetic recovery room for early extubation following an ultra-fast-track protocol and were only transferred to ICU when any instability occurred.
c During first 7 postoperative days.
[ ( ) T D $ F I G ] [ ( ) T D $ F I G ] One of the advantages of T-AVI is the avoidance of CPB as one of the most important risk factors for AKI after cardiac surgery [2] . The present study is a retrospective single-center analysis of renal function after TA-AVI in 270 patients. Nine patients with preoperative dialysis due to chronic kidney disease were excluded. More than half of the patients showed an increased or at least stable eGFR after TA-AVI. This might result from the treatment of the aortic stenosis itself because severe aortic stenosis with concomitant heart failure is one reason for impaired GFR. Other studies have also reported an increased GFR in the majority of patients after T-AVI [5] [6] [7] . AKI occurred in 16.1% of the patients and 15.7% of all patients needed RRT. Approximately one-half of the RRT patients (56.1%) demonstrated AKI and the other 18 patients needed RRT, without demonstrating AKI. One possible reason for this is that the strategy in our institution was to start RRT early. Out of the 18 patients without AKI, 15 had preoperatively impaired eGFR of less than 60 ml min À1 . The RIFLE criteria are based on changes between preoperative and postoperative GFR. Therefore, the patients with RRT and without AKI might have been dialyzed before AKI (as defined according to RIFLE) became apparent based on laboratory analysis with already elevated creatinine levels. Bagur et al. reported an occurrence of AKI in 11.7% of the patients [7] . They based their results on a single analysis of eGFR 48 h after the procedure. By contrast, we based our results on several measurements of eGFR within 7 days. This may result in the higher incidence of AKI in our study. Another reason for a higher incidence of AKI and RRT found in studies reporting exclusively patients in whom a trans-apical approach was used might be due to a more frequent generalized arteriosclerosis and associated reduced renal function in these patients. This is reflected by the fact that a high percentage of our patients presented with calcified All values are expressed as [n/%] or mean AE SD, LOS: length of stay, eGFR: estimated glomerular filtration rate, AKI: acute kidney injury, RRT: renal replacement therapy. a After the procedure all patients were transferred to the post-anesthetic recovery room for early extubation following an ultra-fast-track protocol and were only transferred to ICU when any instability occurred.
b During first 7 postoperative days.
femoral vessels detected with CT scans and, thus, general atherosclerosis. Similarly, in studies comparing transfemoral AVI to TA-AVI, the latter was associated with a higher incidence of AKI [5, 7] .
The 15.7% incidence of RRTwas higher than it is described for conventional aortic valve surgery with 4.5% [2] , but the TA-AVI patients display a high-risk subgroup and are not comparable with an average cohort of patients undergoing cardiac surgery.
AKI as well as RRTwere both associated with a significantly higher 30-day-, in-hospital-and one year mortality rate. This has been previously reported for conventional cardiac surgery [3, 10] . For transcatheter valves Bagur et al. reported a significantly increased mortality in 213 patients, too [7] , but two other studies found no significant differences in mortality in patients with or without AKI after transcatheter valve implantation [5, 6] . However, both studies included much smaller number of patients and both analyses showed a trend to a higher mortality rate in the AKI group, but obviously were statistically underpowered.
We found chronic kidney disease (eGFR < 60 ml h À1 , serum creatinine > 1.1 mg dl À1 ), number of blood transfusions and pathological leucocyte count in terms of systemic inflammatory response syndrome (SIRS) as independent risk factors for RRT. Independent risk factors for AKI were a higher amount of contrast-agent, thrombocytopenia and pathological leucocyte count in terms of SIRS. Surprisingly, chronic kidney disease was not an independent risk factor for AKI. We could not confirm other previously described risk factors for AKI such as diabetes mellitus, arterial hypertension, or chronic obstructive pulmonary disease. All values are expressed as [n/%] or mean AE SD, LOS: length of stay, eGFR: estimated glomerular filtration rate, AKI: acute kidney injury, RRT: renal replacement therapy. a After the procedure all patients were transferred to the post-anesthetic recovery room for early extubation following an ultra-fast-track protocol and were only transferred to ICU when any instability occurred.
There was no statistically significant difference with regard to the timing of cardiac catheterization and CT scan and no difference in the amount of contrast-agent given at preoperative diagnostics. Two previous studies focusing on timing of cardiac catheterization before conventional cardiac surgery showed an increased risk for AKI when cardiac catheterization was performed within 5 days before surgery [11, 12] , while Ranucci et al. showed an increased risk only when cardiac catheterization was performed on the day of surgery or within 24 h [8] . In our study only 19 patients had cardiac catheterization within 24 h. This small number of patients might be a reason why we could not show any significant influence of cardiac catheterization and CT scan timing on developing of AKI or need for RRT. A reduction of preoperative contrast application should, however, remain one of the goals during the screening process of elderly sick patients before T-AVI.
Regarding the amount of intra-operative contrast-agent we could show that patients with RRT and AKI received a higher dose of contrast-agent, which was statistically significant in the RRT group only. In both groups, the number of patients who received a contrast-agent burden greater than 99 ml was significantly higher and it was even an independent risk factor for AKI. In contrast to our findings, three other studies about renal outcome after transcatheter valves did not find any dose-related kidney injury [5] [6] [7] . The reasons for these different findings might be again the timing of detecting AKI in the first study and the small number of patients in the second and third study. The discussion of the influence of contrast-agent on kidney function and the role of contrast induced nephropathy (CIN) are still controversial including the unclear pathogenesis of CIN [1, 13] . The latter seems to be related to acute tubular necrosis due to vasoconstriction, resulting in medullary hypoxemia and to direct toxic effects [14] [15] [16] [17] . Our results correlate with the findings of previous studies about percutaneous coronary intervention where an increase of AKI was found with a contrast-agent burden greater than 100 ml [18] [19] [20] . Due to these diverse results and due to the importance of preventing AKI with its increased mortality further investigation is necessary to finally understand the pathogenesis of CIN and most of all to avoid CIN and AKI. Different ways to reduce the amount of contrast-agent should be both developed and improved. Concepts for fully echocardiographic guided implantations without any contrast application or fully real-time magnetic resonance imaging-guided implantations have been proven [21] [22] [23] . New imaging tools to improve the visualization and thereby reduce the total amount of contrast-agent such as DynaCT (Axiom Artis and Zeego, Siemens Inc, Erlangen, Germany) have already been established [24] .
Aregger et al. also analyzed the changes in postoperative thrombocyte and leucocyte count [5] . Similar to our results, they reported a significant decrease of thrombocytes in all patients with significantly lower thrombocyte counts in patients with AKI and RRT and new thrombocytopenia as an independent risk factor for AKI. Our incidence of new thrombocytopenia was lower with 11.5%. Thrombocytopenia after cardiac surgery is a multifactorial process including drugs, balloon pumps, and intravascular coagulation [25] . The reason for thrombocytopenia after T-AVI is not fully understood yet, especially because CPB as one of the most important risk factors for thrombocytopenia after conventional cardiac surgery is infrequently used in T-AVI. Pathological leucocyte count as an SIRS marker was more common in patients with AKI and RRTand was an independent risk factor for both. These findings are also consistent with Arreger et al. who found SIRS as another potential mechanism for AKI [5] .
A higher number of blood transfusions in patients with AKI and RRT was reported in two studies about AKI after T-AVI [5, 7] . This is consistent to our findings where a number of blood transfusions >5 was also an independent risk factor for RRT. For conventional cardiac surgery, the need for blood transfusions is a well-known predictor of AKI [2] .
Although thrombocytopenia, pathological leucocyte count and the need for blood transfusions statistically turned out as independent risk factors for AKI, RRT, or both, it needs to be discussed whether they really lead to AKI or they are only part of the versatile clinical appearance of AKI as an expression of multiple-organ failure. The RRT itself causes mechanical destruction of thrombocytes, SIRS due to extracorporeal surface and loss of blood as well. 
Limitations
Limitations of this study are some retrospectively collected data with the chance that other potential risk factors have not been included and despite a rather large sample size of 270 still some limitation in the number of patients.
In conclusion, early preoperative contrast-agent burden does not seem to play a critical role for early postoperative renal function after TA-AVI. Furthermore TA-AVI is feasible in a group of high-risk patients and an improvement of GFR can be achieved in most of the patients. Nevertheless, renal outcome should be kept in mind when evaluating the success of TA-AVI because acute kidney injury and the need for renal replacement therapy are very strong risk factors for shortterm and long-term mortality. Preoperative chronic kidney disease with impaired GFR seems to play an important role only for predicting the need for postoperative RRT, but not for predicting AKI according to RIFLE. Improved imaging modalities will lead to a further reduction in contrast use and thus improved outcomes of T-AVI. kidney disease. There certainly is no harm. It is a rather inexpensive drug to use and a lot of interventional radiology units have it as part of their normal protocol.
Dr Van Linden: To answer the second question first, all patients had ACC before the procedure, so we couldn't make a difference if that affects the outcome, because every patient is getting it immediately before and after the procedure. So we couldn't measure any difference.
And to your first question, of course it is quite interesting. That is why I said the aim of the study was to focus on the preop contrast exposition, and we were quite surprised that there was no difference in these groups. And maybe there are not enough patients to power this, because only five patients had both procedures within 24 hours. If you look into the literature, there are some studies about the amount of contrast agent before cardiac surgery, and it varies between 24 hours as a risk factor up to 7 days. So we took these two timings and we couldn't find a difference, but it may be that there were not enough patients for that.
Dr P. Kappetein (Rotterdam, The Netherlands): What strikes me is the high mortality rate in these patients with acute kidney injury. What we know from the surgical literature is that from the patients at dialysis only 20% are alive and the two year mortality is 50%. So the long-term outcome is also very dismal. You expose these patients to a procedure with a high risk, and then the long-term survival is as bad as you showed. So is it really worth doing this procedure in these patients?
Dr Van Linden: I think if you looked at the amount of contrast agent, it is a predictive risk factor, and if you have some opportunities to lower the dose, I think the mortality rate will decrease and so the procedure will be safe again. And an interesting thing is that, at least in our study, we didn't find chronic kidney disease pre-op as a predictive risk factor for acute kidney injury. So you cannot say we should exclude all patients with chronic kidney disease.
Dr Kappetein: No, but if you have a patient with a very low GFR, what is your strategy, knowing the data? Dr Van Linden: We try to reduce the amount of contrast agent during the procedure.
Dr Kappetein: Yes, but you don't always know in advance that you can limit the amount of contrast.
Dr Van Linden: Of course. Dr Kappetein: So this is a factor which is a procedural factor and not a preprocedural factor.
Dr Van Linden: But I think if you have more imaging tools you can be sure, or at least can be more sure, that you can reduce the amount of contrast agent, and that is why all these new tools are developed or improved.
Dr V. Falk (Zurich, Switzerland): Given the high rate of embolic brain lesions visible on MRI, it would be of interest to perform an MRI study of the kidneys to see if there are embolic lesions as well.
Dr N. Moat (London, UK): I was just going to say the same thing. It is a nice concept, but it may not just be contrast-induced nephropathy. If we are getting this high incidence of microvascular lesions in the brain, it would not be a surprise if we were getting microvascular lesions elsewhere and that might explain the difference.
Dr E. Wolner (Vienna, Austria): The answer to your study is to avoid contrast media by the implantation. Now you have a huge experience. Do you believe that with gaining experience you can perform this procedure only under ultrasound guidance?
Dr Van Linden: There were I think two studies about TEE-guided transapical aortic valve implantation, and they showed that it is feasible in a small number of patients. And there are some developments in MRI-guided implantation; it is just an animal trial. So maybe this can be part of the implantation but not yet I think.
